Press Release Archive

December 1, 2011 - Pfizer Completes Acquisition of Excaliard

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. “It is imperative at Pfizer that we continue to develop new and innovative treatments to address unmet medical needs, and there is currently no FDA-

November 30, 2011 - Pfizer Completes Acquisition of Ferrosan Consumer Health’s Business

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has completed its previously announced acquisition of Ferrosan Consumer Health’s business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited. “Ferrosan Consumer Health’s innovative products and geographic footprint are a strong fit for our business,” said Paul Sturman, President, Pfizer Consumer Healthcare. “Today, we have taken

November 30, 2011 - New Research Initiative Examines Economic Impact of Smoke-free Policies on Restaurants and Bars

(BUSINESS WIRE)--As part of ongoing efforts to reduce disease and death caused by smoking and secondhand smoke exposure, the CDC Foundation and CDC have launched a new initiative to study the economic impact of smoke-free policies on restaurants and bars in nine states. Previous research shows that smoke-free policies that prohibit smoking in workplaces and public places, including restaurants and bars, reduce nonsmokers’ exposure to

November 28, 2011 - FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

(BUSINESS WIRE)--PRINCETON, N.J.

November 21, 2011 - Pfizer to Acquire Excaliard Pharmaceuticals

(BUSINESS WIRE)--NEW YORK

November 21, 2011 - Pfizer And MIT Break Ground On New Research Units In Kendall Square

(BUSINESS WIRE)--Pfizer Inc. and the Massachusetts Institute of Technology (MIT) today held the official groundbreaking of the new location of Pfizer's Cardiovascular, Metabolic and Endocrine Diseases (CVMED) and Neuroscience research units at 610 Main Street, Cambridge, MA. In September, Pfizer announced it had entered into a 10-year lease agreement with MIT for more than 180,000 square feet. Taking part in the

November 20, 2011 - Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA). Validation means that the EMA has confirmed that the application is complete and the agency is beginning its review procedure

November 17, 2011 - Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program

(BUSINESS WIRE)--Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center’s Corporate Citizenship Award in the Best International Ambassador category for Pfizer’s Global Health Partnerships program. The “Citizens” Awards honor excellence in corporate citizenship and civic leadership for initiatives in both the United States and across the world. “The essence of a successful corporate social

November 16, 2011 - Pfizer’s Vyndaqel® (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)

(BUSINESS WIRE)--Pfizer announced today that the European Commission has approved Vyndaqel® (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. TTR-FAP is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide. 1,2,3 “A diagnosis of TTR-FAP, usually made in patients during their mid-

November 16, 2011 - The Advil® Congestion Relief Project Hits the Road to Relieve Congestion in Communities

(BUSINESS WIRE)--Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, yesterday, kicked off a nationwide effort to make a difference in communities. The cold and flu brand is putting a twist on its tagline – “The Right Relief for the Real Problem,” and providing literal relief in congested places across the US. In its first relief stop, The Advil® Congestion Relief Project unveiled a new library at P.S. 130 in the Bronx.

November 14, 2011 - Kathryn Joosten Speaks Out About Lung Cancer Profiles; ‘Desperate’ to Share Her Personal Lung Cancer Story to Help Others

(BUSINESS WIRE)--Kathryn Joosten, two-time Emmy® Award-winning actress and star of Desperate Housewives and The West Wing, is opening up about her 10-year battle with lung cancer as part of a new national campaign, Lung Cancer Profiles. Lung Cancer Profiles aims to reduce the stigma associated with lung cancer by educating about the diversity of the disease inside and out. The campaign, created by Pfizer Oncology in collaboration with the

November 12, 2011 - New Data Presented On Phase 3 Trial Of ELIQUIS® (apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical Illness

(BUSINESS WIRE)--PRINCETON, N.J.

November 7, 2011 - Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency. The study met its primary endpoint, as treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urinary urgency episodes overnight

November 7, 2011 - Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd Annual Meeting Of The American Society Of Hematology

(BUSINESS WIRE)--Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML),1 inotuzumab in non-Hodgkin lymphoma (NHL),2 as well as the first presentation of clinical data for PF-04449913,3 which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.4 In addition, ongoing investigator-initiated research on gemtuzumab

November 5, 2011 - Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients with Moderately Active Disease

(BUSINESS WIRE)--THOUSAND OAKS, Calif.

October 31, 2011 - Pfizer Reports Third-Quarter 2011 Results

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter(4) Year-to-Date(4) 2011 2010 Change

October 27, 2011 - Pfizer Completes Acquisition Of Icagen

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer. Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6.00 in cash, without interest thereon, and

October 27, 2011 - Pfizer Declares A 20-Cent Fourth-Quarter 2011 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent fourth-quarter 2011 dividend on the company’s common stock, payable December 6, 2011, to shareholders of record at the close of business on November 11, 2011. The fourth-quarter 2011 cash dividend will be the 292nd consecutive quarterly dividend paid by Pfizer.

October 26, 2011 - Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has established a research collaboration with Medco Health Solutions, Inc. (NYSE: MHS) and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes. The collaboration is intended to enhance Pfizer’s precision medicine approach, which

October 26, 2011 - Pfizer Establishes Precision Medicine Research Collaboration With Medco

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.